Consumer Tech Growth to Reset in 2026 as Demand Shifts to Europe and MEA
4.1.2026 14:00:00 EET | Business Wire | Press release
NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its 2026 Consumer Tech & Durable Goods (T&D) market outlook. In collaboration with the Consumer Technology Association (CTA), NIQ expects T&D global sales to level off in 2026 after a strong 2025. The sector is set to finish 2025 at roughly $1.3 trillion USD, up 3% from 2024, while 2026 overall sales value is projected to hold steady at an estimated -0.4% year over year (YoY).
While the global picture looks flat, the real story lies in the differences in regional and sector performance. Consumers overall remain careful with their spending and are prioritizing value for money—with a focus on products that offer enhanced performance, convenience, energy-saving, and/or durability. Brands and retailers that align pricing, innovation, and experience to region- and category-specific demand will win share of wallet.
“In 2025, global Consumer Tech & Durable goods purchases grew by a solid 3%. Growth is expected to slow in 2026, but most regions should remain stable or see modest gains. The exception is China, where elevated baselines from recent trade-in policies will weigh on performance,” said Julian Baldwin, President of Tech & Durables at NIQ. “Looking ahead, the next phase of growth will rely less on broad market recovery and more on how effectively brands tailor innovation, pricing, and features to meet local consumer expectations.”
Key insights and emerging trends for 2026 include:
- Market Outlook: Consumer Tech & Durable Goods sales are projected to reach $1.3T in 2025 (+3% vs. 2024), before softening slightly in 2026 (-0.4% YoY). Growth will be led by Eastern Europe (+5%), Western Europe (+3%), MEA (+3%), and Latin America (+2%), while North America holds steady and Asia-Pacific declines (-3%, driven by China at -5%).
- Sector Trends: Small Domestic Appliances (SDA) will grow, IT & Office will see modest gains, Major Domestic Appliances remain stable, and Telecom and Consumer Electronics experience slight declines.
- Consumer & Product Dynamics: Value-for-money remains a top priority, meaning that product benefits must be both highly relevant and visible to shoppers. Replacement cycles for PCs and smartphones, combined with premiumization trends—AI-native PCs, Mini LED/OLED TVs, built-in appliances, and smart home appliances—will help drive demand. TVs get a boost from the 2026 World Cup, while open-ear headsets sustain momentum, and AI-enabled features with clear use cases offer premiumization potential.
- Strategic Considerations: Focus growth strategies on high-potential markets by volume and value. Monitor policy and trade factors, including evolving U.S. tariffs, China’s trade-in programs, and expanding competition from Chinese brands entering new markets, as affordability and accessibility drive AI adoption globally.
“Despite easing inflation and resilient demand in many regions, risks from tariffs and supply chain disruptions persist,” said Steve Koenig, Vice President of Research, Consumer Technology Association. “Consumers remain value-driven but are prepared to spend where they see compelling product features. Built-in Artificial Intelligence continues to present strong opportunity as a product differentiator, but adoption will depend on clear use cases that illustrate direct benefits and ROI.”
The outlook comes as NIQ leaders—including Julie Kenar, SVP Automotive Business, and Sherry Frey, VP Total Wellness—prepare to share insights at CES 2026, taking place January 6-9 in Las Vegas. For deeper insights, explore NIQ’s 2026 market estimate for Consumer Tech & Durable Goods.
About NIQ
NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. Our global reach spans over 90 countries covering approximately 85% of the world’s population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.
For more information, please visit: www.niq.com
About Consumer Technology Association
As North America’s largest technology trade association, CTA®is the tech sector. Our members are the world’s leading innovators — from startups to global brands — helping support more than 18 million American jobs. CTA owns and produces CES® — the most influential tech event in the world. Find us at CTA.tech. Follow us @CTAtech.
Forward-Looking Statements Disclaimer
This Consumer Tech Outlook release may contain forward-looking statements regarding anticipated consumer behaviors, market trends, and industry developments. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as “expects,” “will,” “anticipates,” “projects,” “believes,” “forecasts,” “estimate,” and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.
Note to Editors
NIQ’s Consumer Tech & Durable Goods (T&D) experts, working with the Consumer Technology Association, model their 2026 Consumer Tech market estimate using long-term and current trend data. Our market growth estimate assumes that China continues a level of financial support for their domestic market in 2026, but not to the extent seen in 2025, model their 2026 Consumer Tech market estimate using long-term and current trend data. Our market growth estimate assumes that China continues a level of financial support for their domestic market in 2026, but not to the extent seen in 2025.
Disclaimer
All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
© 2026 Nielsen Consumer LLC. All Rights Reserved.
NIQ-GENERAL
View source version on businesswire.com: https://www.businesswire.com/news/home/20260104140033/en/
Contacts
Media Contact: media.relations@niq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom